Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 Jun 4, 2025 04:34PM
Bio-Path Holdings (BPTH) Expands Global Patent Portfolio Feb 13, 2025 04:02PM
Bio-Path Holdings (BPTH) Provides Key Clinical Updates Feb 13, 2025 08:01AM
Bio-Path Holdings (BPTH) provides update on clinical trial of BP1002 Feb 12, 2025 04:02PM
Bio-Path Holdings (BPTH) Provides 2025 Clinical and Operational Update Jan 10, 2025 07:06AM


Dec 19, 2024 07:02AM Bio-Path Holdings (BPTH) Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
Dec 13, 2024 04:44PM Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24
Dec 11, 2024 07:02AM Bio-Path Holdings (BPTH) Outlines Rationale for Development of BP1001-A
Nov 15, 2024 06:52AM Bio-Path Holdings (BPTH) Misses Q3 EPS by 70c
Oct 17, 2024 04:47PM Bio-Path Holdings (BPTH) files for up to 17,757,844 share offering by selling stockholders
Oct 9, 2024 06:01AM Bio-Path Holdings (BPTH) Prices $4M Share Offering at $0.87/sh
Oct 8, 2024 07:24AM Bio-Path Holdings (BPTH) Initiates Development of Therapeutic Program for Treatment of Obesity
Sep 4, 2024 05:48PM Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
Aug 21, 2024 10:51AM Roth/MKM Reiterates Buy Rating on Bio-Path Holdings (BPTH)
Aug 21, 2024 07:05AM Bio-Path Holdings (BPTH) Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
Aug 15, 2024 07:21AM Bio-Path Holdings (BPTH) Reports Q2 Loss of $1.16/sh
Jun 11, 2024 05:33PM Bio-Path Holdings (BPTH) Files for 5.57M Share Offering by Selling Stockholders